FDAnews
www.fdanews.com/articles/174921-mannkind-withdraws-employment-offer-to-desisto

MannKind Withdraws Employment Offer to DeSisto

January 15, 2016

It’s been a rough new year for MannKind. Days after it announced the termination of a deal with Sanofi for its inhaled insulin Afrezza, the Valencia, Calif.-based drugmaker has withdrawn its offer to employ Duane DeSisto as its new CEO.

The move comes after DeSisto’s former employer, devicemaker Insulet, said hiring him would violate a noncompetition agreement.  DeSisto helmed Insulet from 2003 until 2014; he was set to assume the role at MannKind Jan. 5. However, according to Insulet, the noncompetition agreement is in effect through Sept. 17.

Matthew Pfeffer, current chief financial officer of MannKind, has been appointed the new CEO, effective Jan. 10. He takes over from Alfred Mann, who had served as interim CEO since the resignation of Hakan Edstrom in November.